- Home
- ADVM vs ATRA Comparison
ADVM vs ATRA Comparison
Compare ADVM & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- ATRA
- Stock Information
- Founded
- ADVM 2006
- ATRA 2012
- Country
- ADVM United States
- ATRA United States
- Employees
- ADVM N/A
- ATRA N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADVM Health Care
- ATRA Health Care
- Exchange
- ADVM Nasdaq
- ATRA Nasdaq
- Market Cap
- ADVM 47.4M
- ATRA 51.1M
- IPO Year
- ADVM 2014
- ATRA 2014
- Fundamental
- Price
- ADVM $2.39
- ATRA $11.52
- Analyst Decision
- ADVM Strong Buy
- ATRA Strong Buy
- Analyst Count
- ADVM 5
- ATRA 4
- Target Price
- ADVM $23.80
- ATRA $20.00
- AVG Volume (30 Days)
- ADVM 122.9K
- ATRA 65.8K
- Earning Date
- ADVM 08-11-2025
- ATRA 08-11-2025
- Dividend Yield
- ADVM N/A
- ATRA N/A
- EPS Growth
- ADVM N/A
- ATRA N/A
- EPS
- ADVM N/A
- ATRA N/A
- Revenue
- ADVM $1,000,000.00
- ATRA $199,732,000.00
- Revenue This Year
- ADVM N/A
- ATRA N/A
- Revenue Next Year
- ADVM $18.82
- ATRA N/A
- P/E Ratio
- ADVM N/A
- ATRA N/A
- Revenue Growth
- ADVM N/A
- ATRA 475.53
- 52 Week Low
- ADVM $1.78
- ATRA $5.01
- 52 Week High
- ADVM $8.56
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- ADVM 42.53
- ATRA 62.05
- Support Level
- ADVM $2.61
- ATRA $10.68
- Resistance Level
- ADVM $2.82
- ATRA $12.85
- Average True Range (ATR)
- ADVM 0.21
- ATRA 1.07
- MACD
- ADVM -0.03
- ATRA 0.07
- Stochastic Oscillator
- ADVM 8.57
- ATRA 60.65
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).